MarketNorpsilocin
Company Profile

Norpsilocin

Norpsilocin, also known as 4-hydroxy-N-methyltryptamine (4-HO-NMT), is a tryptamine alkaloid recently discovered in 2017 in the psychedelic mushroom Psilocybe cubensis. It is hypothesized to be a dephosphorylated metabolite of baeocystin.

Pharmacology
Norpsilocin was found to be a near full agonist of the 5-HT2A receptor and was found to be more potent than psilocin. It also has affinity for other serotonin receptors. Norpsilocin has shown psilocin-related peripheral effects in animals, including decreased spinal reflexes such as knee jerk response (opposite effect to psilocin), antiserotonergic activity (14% of that of psilocin), and pressor activity (70% of that of psilocin). Surprisingly however, in spite of its serotonin 5-HT2A receptor agonism and psilocin-like effects, norpsilocin failed to induce the head-twitch response, a behavioral proxy of psychedelic effects, in animals. ==Research==
Research
Norpsilocin is being evaluated under the developmental code name PLZ-1017 for the possible treatment of pervasive developmental disorders in children. ==See also==
tickerdossier.comtickerdossier.substack.com